Wang Chen (1st R), vice president of the Chinese Academy of Engineering and president of the Chinese Academy of Medical Sciences (CAMS), speaks at a conference in Wuhan, central China's Hubei Province, Feb. 5, 2020. (Xinhua/Cheng Min)
Several antiviral drugs have been applied in clinical trials against the novel coronavirus disease (COVID-19), and some have shown fairly good clinical efficacy, according to an official Saturday.
Chinese researchers have narrowed down their focus to a few existing drugs, including Chloroquine Phosphate, Favipiravir and Remdesivir, after multiple rounds of screening, said Zhang Xinmin, director of the China National Center for Biotechnology Development under the Ministry of Science and Technology, at a press conference on the new virus.
The researchers scanned more than 70,000 drugs or compounds through computer simulations and in vitro enzyme activity tests, and selected 5,000 potentially effective drug candidates, Zhang said.
Then they were tested at the cellular level against the common coronavirus infection, and about 100 drugs were chosen for further experiments, which helped to select the final drugs for clinical trials, Zhang said.
